Weekly Analysts’ Ratings Changes for LeMaitre Vascular (LMAT)

LeMaitre Vascular (NASDAQ: LMAT) recently received a number of ratings updates from brokerages and research firms:

  • 10/10/2018 – LeMaitre Vascular was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
  • 10/9/2018 – LeMaitre Vascular was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/9/2018 – LeMaitre Vascular was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $32.00 price target on the stock. According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
  • 10/8/2018 – LeMaitre Vascular was upgraded by analysts at Barrington Research from a “market perform” rating to an “outperform” rating. They now have a $34.00 price target on the stock. They wrote, “We are upgrading our investment rating on LMAT shares to OUTPERFORM (from MARKET PERFORM previously). We think that Friday’s trading action that resulted in a 20.7% downdraft in LMAT’s market value was overdone and provides investors with an attractive entry point. We have always liked this business and its leadership but had found stock valuation a recurring challenge when assessing this idea – until Friday, that is. Our price target is $34. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now.””
  • 10/8/2018 – LeMaitre Vascular had its price target lowered by analysts at Canaccord Genuity from $40.00 to $32.00. They now have a “hold” rating on the stock.
  • 10/8/2018 – LeMaitre Vascular was upgraded by analysts at Roth Capital from a “neutral” rating to a “buy” rating. They now have a $34.00 price target on the stock, down previously from $39.00.
  • 10/6/2018 – LeMaitre Vascular was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/5/2018 – LeMaitre Vascular was downgraded by analysts at Lake Street Capital from a “buy” rating to a “hold” rating.
  • 10/2/2018 – LeMaitre Vascular was downgraded by analysts at Roth Capital from a “buy” rating to a “neutral” rating. They now have a $39.00 price target on the stock, up previously from $38.00.
  • 9/28/2018 – LeMaitre Vascular was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/26/2018 – LeMaitre Vascular was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
  • 9/8/2018 – LeMaitre Vascular was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

LMAT traded up $0.32 during midday trading on Friday, hitting $28.25. 17,627 shares of the company were exchanged, compared to its average volume of 151,624. The company has a market capitalization of $748.16 million, a PE ratio of 32.85, a PEG ratio of 2.42 and a beta of 0.63. LeMaitre Vascular Inc has a 1-year low of $26.45 and a 1-year high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.21. The company had revenue of $24.17 million for the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. Equities research analysts forecast that LeMaitre Vascular Inc will post 1.07 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s dividend payout ratio is 32.56%.

In other news, Chairman George W. Lemaitre sold 39,820 shares of the business’s stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $37.34, for a total value of $1,486,878.80. Following the transaction, the chairman now directly owns 3,085,291 shares of the company’s stock, valued at approximately $115,204,765.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 22,000 shares of the business’s stock in a transaction dated Wednesday, July 25th. The shares were sold at an average price of $37.26, for a total value of $819,720.00. Following the completion of the transaction, the chief executive officer now directly owns 3,085,291 shares in the company, valued at $114,957,942.66. The disclosure for this sale can be found here. Insiders sold a total of 97,506 shares of company stock worth $3,608,759 over the last three months. 20.30% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in LeMaitre Vascular in the 1st quarter valued at about $600,000. SG Americas Securities LLC bought a new stake in LeMaitre Vascular in the 2nd quarter valued at about $394,000. Royce & Associates LP increased its position in LeMaitre Vascular by 90.8% in the 2nd quarter. Royce & Associates LP now owns 83,374 shares of the medical instruments supplier’s stock valued at $2,791,000 after buying an additional 39,683 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new stake in LeMaitre Vascular in the 2nd quarter valued at about $263,000. Finally, Swiss National Bank increased its position in LeMaitre Vascular by 13.2% in the 2nd quarter. Swiss National Bank now owns 30,100 shares of the medical instruments supplier’s stock valued at $1,008,000 after buying an additional 3,500 shares in the last quarter. 79.75% of the stock is currently owned by institutional investors.

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for LeMaitre Vascular Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply